These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 39037853)

  • 21. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
    Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
    Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Waiving Coinsurance for Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test in a Medicare Population.
    Fendrick AM; Lieberman D; Vahdat V; Chen JV; Ozbay AB; Limburg PJ
    Cancer Prev Res (Phila); 2022 Oct; 15(10):653-660. PubMed ID: 35768200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
    Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
    Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.
    Lwin MW; Cheng CY; Calderazzo S; Schramm C; Schlander M
    Front Public Health; 2024; 12():1307427. PubMed ID: 38454984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests.
    Meester RGS; Ladabaum U
    JNCI Cancer Spectr; 2024 Sep; 8(5):. PubMed ID: 39240660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colon Cancer Screening - Is It Time Yet?
    Bhurgri H; Samiullah S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes.
    Kisiel JB; Itzkowitz SH; Ozbay AB; Saoud L; Parton M; Lieberman D; Limburg PJ
    Gastro Hep Adv; 2022; 1(1):55-62. PubMed ID: 39129937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
    Ladabaum U; Mannalithara A; Weng Y; Schoen RE; Dominitz JA; Desai M; Lieberman D
    Gastroenterology; 2024 Jul; 167(2):378-391. PubMed ID: 38552670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The health economic impact of varying levels of adherence to colorectal screening on providers and payers.
    Hathway JM; Miller-Wilson LA; Yao W; Jensen IS; Weinstein MC; Parks PD
    J Med Econ; 2021; 24(1):69-78. PubMed ID: 33970747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population.
    Karlitz JJ; Fendrick AM; Bhatt J; Coronado GD; Jeyakumar S; Smith NJ; Plescia M; Brooks D; Limburg P; Lieberman D
    Popul Health Manag; 2022 Jun; 25(3):343-351. PubMed ID: 34958279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of single colonoscopy versus single fecal test for colorectal cancer diagnosis and treatment.
    Ishibashi F; Suzuki S; Kobayashi K; Tanaka R; Kawakami T; Mochida K; Nagai M; Ishibashi Y; Morishita T
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1328-1335. PubMed ID: 38348570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness Analysis of Colorectal Cancer Screening Strategies Using Active Learning and Monte Carlo Simulation.
    Fouladi A; Asadi A; Sherer EA; Madadi M
    Med Decis Making; 2024 Jul; 44(5):554-571. PubMed ID: 38907706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.
    Naber SK; Knudsen AB; Zauber AG; Rutter CM; Fischer SE; Pabiniak CJ; Soto B; Kuntz KM; Lansdorp-Vogelaar I
    PLoS One; 2019; 14(9):e0220234. PubMed ID: 31483796
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.